For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

Issuers still hold the key role in fighting fraud without compromising customer experience. A proactive issuer strategy ...

Check the time stamp on this data. Updated AI-Generated Signals for Centerpoint Energy Inc (holding Co) (CNP) available here: ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...

CenterPoint Energy Inc. closed $3.40 short of its 52-week high ($31.57), which the company achieved on June 21st.

(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...

In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...

“Thank you so much. Honestly, the things that we run out of and that we’re low on the most are mattresses, bed frames, linens ...

First Day of Fall Arrives across the Gulf Coast Region, but Hurricane Season Remains in Full Force <li /> CenterPoint <a ...

Copenhagen-based Ascendis designed the trial to compare its once-weekly prodrug of C-type natriuretic peptide (CNP) to ...

CenterPoint Energy Inc. closed $3.31 below its 52-week high ($31.57), which the company reached on June 21st.